Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2026-03-03 @ 6:36 AM
Study NCT ID:
NCT01875666
Status:
COMPLETED
Last Update Posted:
2020-09-04
First Post:
2013-06-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
LCCC 1214
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None